Phase 3 Asthma Research Study

Asthma is one of the most common chronic diseases which affects the airways of the lungs. During acute asthmatic episodes, the airway passages become narrower and more obstructed, resulting in coughing, wheezing, tightness of the chest, shortness of breath, and increased mucus production. Asthma can cause irreversible changes in the airway structure and function which can increase morbidity and mortality.

Asthma is commonly treated with inhalers that contain medicines which help to reduce inflammation and swelling in the airways. To deliver these medicines into the lungs, these inhalers use a special type of medical gas known as a propellant. A common approved propellant is called HFA. HFA propellant is known to contribute to global warming and many countries will soon have laws which stop it from being used in inhalers. This means that more environmentally friendly propellants are needed to make sure asthma treatment can continue to be available globally.

This study is investigating a new propellant called HFO, which is more environmentally friendly than HFA. The inhalers in this study will contain a treatment called budesonide and albuterol (BDA). BDA is already a well-established treatment for asthma. The study will assess whether BDA using HFO is as good at delivering BDA into the lungs as the BDA using HFA, and is as effective at reducing airway inflammation.